CS
CRNX

Candriam SCA’s Crinetics Pharmaceuticals CRNX Stock Holding History

Candriam SCA’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.6M Sell
819,032
-11,929
-1% -$443K 0.14% 150
2026
Q1 		$30.2M Hold
830,961
– – 0.16% 140
2025
Q4 		$38.7M Buy
830,961
+85,867
+12% +$3.82M 0.19% 121
2025
Q3 		$31M Buy
745,094
+51,225
+7% +$1.64M 0.16% 130
2025
Q2 		$20M Buy
693,869
+204,958
+42% +$6.33M 0.12% 165
2025
Q1 		$16.4M Buy
+488,911
New +$18.3M 0.1% 181
2024
Q2 		– Sell
-88,005
Closed -$4.12M – 695
2024
Q1 		$4.12M Sell
88,005
-200,006
-69% -$7.83M 0.03% 375
2023
Q4 		$10.2M Buy
+288,011
New +$8.83M 0.07% 245

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Candriam SCA's CRNX Position: Q2 2026 in Review

Candriam SCA reduced its Crinetics Pharmaceuticals (CRNX) stake by 1.4% in Q2 2026, selling an estimated $443K and leaving 819,032 shares worth $30.6M. The position accounts for 0.14% of the portfolio, ranked #150.

Candriam SCA first reported a position in CRNX in Q4 2023 and has held it in 8 quarters since. The position peaked at $38.7M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Candriam SCA held 819,032 shares of Crinetics Pharmaceuticals worth $30.6M as of Q2 2026.
  • Candriam SCA sold 11,929 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $443K.
  • Crinetics Pharmaceuticals made up 0.14% of Candriam SCA's portfolio in Q2 2026, its #150 holding.
  • Candriam SCA first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • Candriam SCA's Crinetics Pharmaceuticals position peaked at $38.7M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.